Aging Itself as a Trial Target
Placeholder: TAME reframes aging as a treatable condition, not a backdrop.
- Metformin: Proposed drug (Placeholder note)
- 2015: Trial concept year (Placeholder note)
- Age 65–79: Target population (Placeholder note)
- N. Barzilai: Lead investigator (Placeholder note)
Why aging qualifies as an indication
Placeholder: short rationale for treating aging as a single modifiable process.
Composite Multi-Morbidity Endpoint Design
Placeholder: one endpoint bundles heart disease, cancer, dementia, and death.
- 4+: Endpoint diseases (Placeholder note)
- Time-to-event: Primary metric (Placeholder note)
- Multi-morbidity: Composite type (Placeholder note)
- Cox hazard: Statistical model (Placeholder note)
Bundling diseases into one measurable outcome
Placeholder: short description of how the composite endpoint is built.
Time-to-First-Age-Related-Disease Outcome
Placeholder: each participant is followed until their first qualifying event.
- First event: Outcome type (Placeholder note)
- Survival curves: Tracking method (Placeholder note)
- Placebo arm: Comparator (Placeholder note)
- ~2–3 yrs: Expected delay (Placeholder note)
Modeling delayed disease onset
Placeholder: short description of time-to-first-disease modeling.
Large Elderly Cohort Recruitment
Placeholder: thousands of older adults recruited across many clinical sites.
- 3,000: Planned cohort (Placeholder note)
- ~14: Site count (Placeholder note)
- 65–79: Age range (Placeholder note)
- 5–6 yrs: Follow-up (Placeholder note)
Recruiting a representative elderly cohort
Placeholder: short description of recruitment and site strategy.
Regulatory Precedent for Anti-Aging Trials
Placeholder: TAME could establish an FDA pathway for aging indications.
- Novel: FDA pathway (Placeholder note)
- None: Prior precedent (Placeholder note)
- Pending: Funding status (Placeholder note)
- High: Field impact (Placeholder note)
Opening the door for future geroprotector trials
Placeholder: short description of downstream regulatory impact.
Placeholder: short callout on why this precedent matters for the field.